Competitive inhibition of the luminal efflux by multidrug and toxin extrusions, but not basolateral uptake by organic cation transporter 2, is the likely mechanism underlying the pharmacokinetic drug-drug interactions caused by cimetidine in the kidney

Journal of Pharmacology and Experimental Therapeutics

Volumn 340, Issue 2, 2012, Pages 393-403

  Ito, Sumito ^a   Kusuhara, Hiroyuki ^a   Yokochi, Miyu ^a   Toyoshima, Junko ^a   Inoue, Katsuhisa ^b   Yuasa, Hiroaki ^b   Sugiyama, Yuichi ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b NAGOYA CITY UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

(3 IODOBENZYL)GUANIDINE; 1 METHYL 4 PHENYLPYRIDINIUM; 4 [4 (DIMETHYLAMINO)STYRYL] N METHYLPYRIDINIUM; CARRIER PROTEIN; CEFALEXIN; CIMETIDINE; METFORMIN; MULTIDRUG AND TOXIN EXTRUSION 1; MULTIDRUG AND TOXIN EXTRUSION 2 K; ORGANIC CATION TRANSPORTER 1; ORGANIC CATION TRANSPORTER 2; PYRIDINIUM DERIVATIVE; TETRYLAMMONIUM; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL STRAIN HEK293; COMPETITIVE INHIBITION; CONCENTRATION RESPONSE; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG ELIMINATION; DRUG INFUSION; DRUG INHIBITION; DRUG LIVER LEVEL; DRUG POTENCY; DRUG TRANSPORT; DRUG URINE LEVEL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INHIBITION KINETICS; KIDNEY CLEARANCE; KIDNEY SLICE; LIQUID CHROMATOGRAPHY; MALE; MOLECULAR PROBE; MOUSE; NONHUMAN; PRIORITY JOURNAL; STEADY STATE; TANDEM MASS SPECTROMETRY;

1-METHYL-4-PHENYLPYRIDINIUM; 3-IODOBENZYLGUANIDINE; ANIMALS; BINDING, COMPETITIVE; BIOLOGICAL TRANSPORT; CEPHALEXIN; CIMETIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; HEK293 CELLS; HUMANS; KIDNEY; KINETICS; LIVER; MALE; METFORMIN; MICE; MICE, INBRED STRAINS; ORGANIC CATION TRANSPORT PROTEINS; ORGANIC CATION TRANSPORTER 1; PYRIDINES; TETRAETHYLAMMONIUM; TRANSFECTION;

EID: 84855995429     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.111.184986     Document Type: Article

References (43)

1. Abel S, Nichols DJ, Brearley CJ, and Eve MD (2000) Effect of cimetidine and ranitidine on pharmacokinetics and pharmacodynamics of a single dose of dofetilide. Br J Clin Pharmacol 49:64-71. (Pubitemid 30050488)
2. Bendayan R, Sullivan JT, Shaw C, Frecker RC, and Sellers EM (1990) Effect of cimetidine and ranitidine on the hepatic and renal elimination of nicotine in humans. Eur J Clin Pharmacol 38:165-169. (Pubitemid 20097323)
3. Biermann J, Lang D, Gorboulev V, Koepsell H, Sindic A, Schröter R, Zvirbliene A, Pavenstädt H, Schlatter E, and Ciarimboli G (2006) Characterization of regulatory mechanisms and states of human organic cation transporter 2. Am J Physiol Cell Physiol 290:C1521-C1531. (Pubitemid 43830792)
4. Blake GM, Lewington VJ, Zivanovic MA, and Ackery DM (1989) Glomerular filtration rate and the kinetics of 123I-metaiodobenzylguanidine. Eur J Nucl Med 15:618-623. (Pubitemid 19236006)
5. Busch AE, Karbach U, Miska D, Gorboulev V, Akhoundova A, Volk C, Arndt P, Ulzheimer JC, Sonders MS, Baumann C, et al. (1998) Human neurons express the polyspecific cation transporter hOCT2, which translocates monoamine neurotransmitters, amantadine, and memantine. Mol Pharmacol 54:342-352. (Pubitemid 28368824)
6. Christian CD Jr, Meredith CG, and Speeg KV Jr (1984) Cimetidine inhibits renal procainamide clearance. Clin Pharmacol Ther 36:221-227. (Pubitemid 14064853)
7. Dudley AJ, Bleasby K, and Brown CD (2000) The organic cation transporter OCT2 mediates the uptake of β-adrenoceptor antagonists across the apical membrane of renal LLC-PK(1) cell monolayers. Br J Pharmacol 131:71-79.
8. Feng B, Obach RS, Burstein AH, Clark DJ, de Morais SM, and Faessel HM (2008) Effect of human renal cationic transporter inhibition on the pharmacokinetics of varenicline, a new therapy for smoking cessation: an in vitro-in vivo study. Clin Pharmacol Ther 83:567-576. (Pubitemid 351417059)
9. Fish DN and Chow AT (1997) The clinical pharmacokinetics of levofloxacin. Clin Pharmacokinet 32:101-119. (Pubitemid 27104410)
10. Fletcher CV, Henry WK, Noormohamed SE, Rhame FS, and Balfour HH Jr (1995) The effect of cimetidine and ranitidine administration with zidovudine. Pharmacotherapy 15:701-708.
11. International Transporter Consortium, Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KL, Chu X, Dahlin A, Evers R, Fischer V, et al. (2010) Membrane transporters in drug development. Nat Rev Drug Discov 9:215-236.
12. Ito S, Kusuhara H, Kuroiwa Y, Wu C, Moriyama Y, Inoue K, Kondo T, Yuasa H, Nakayama H, Horita S, et al. (2010) Potent and specific inhibition of mMate1-mediated efflux of type I organic cations in the liver and kidney by pyrimethamine. J Pharmacol Exp Ther 333:341-350.
13. Jonker JW, Wagenaar E, Van Eijl S, and Schinkel AH (2003) Deficiency in the organic cation transporters 1 and 2 (Oct1/Oct2 [Slc22a1/Slc22a2]) in mice abolishes renal secretion of organic cations. Mol Cell Biol 23:7902-7908. (Pubitemid 37271485)
14. Kalvass JC, Maurer TS, and PollackGM(2007) Use of plasma and brain unbound fractions to assess the extent of brain distribution of 34 drugs: comparison of unbound concentration ratios to in vivo p-glycoprotein efflux ratios. Drug Metab Dispos 35:660-666. (Pubitemid 46513270)
15. Kirch W, Rose I, Klingmann I, Pabst J, and Ohnhaus EE (1986) Interaction of bisoprolol with cimetidine and rifampicin. Eur J Clin Pharmacol 31:59-62. (Pubitemid 16017453)
16. Kusuhara H, Ito S, Kumagai Y, Jiang M, Shiroshita T, Moriyama Y, Inoue K, Yuasa H, and Sugiyama Y (2011) Effects of a MATE protein inhibitor, pyrimethamine, on the renal elimination of metformin at oral microdose and at therapeutic dose in healthy subjects. Clin Pharmacol Ther 89:837-844.
17. Kusuhara H and Sugiyama Y (2008) Drug-drug interactions involving the membrane transport process, in Drug-Drug Interactions (Rodrigues AD ed) pp 135-204, Marcel Dekker, New York.
18. Lai MY, Jiang FM, Chung CH, Chen HC, and Chao PD (1988) Dose dependent effect of cimetidine on procainamide disposition in man. Int J Clin Pharmacol Ther Toxicol 26:118-121. (Pubitemid 18068557)
19. Lowry OH, Rosebrough NJ, Farr AL, and Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193:265-275.
20. Matsushima S, Maeda K, Inoue K, Ohta KY, Yuasa H, Kondo T, Nakayama H, Horita S, Kusuhara H, and Sugiyama Y (2009) The inhibition of human multidrug and toxin extrusion 1 is involved in the drug-drug interaction caused by cimetidine. Drug Metab Dispos 37:555-559.
21. Muirhead MR, Somogyi AA, Rolan PE, and Bochner F (1986) Effect of cimetidine on renal and hepatic drug elimination: studies with triamterene. Clin Pharmacol Ther 40:400-407. (Pubitemid 16009040)
22. Müller J, Lips KS, Metzner L, Neubert RH, Koepsell H, and BrandschM(2005) Drug specificity and intestinal membrane localization of human organic cation transporters (OCT). Biochem Pharmacol 70:1851-1860. (Pubitemid 41612016)
23. Nies AT, Koepsell H, Damme K, and Schwab M (2011) Organic cation transporters (OCTs, MATEs), in vitro and in vivo evidence for the importance in drug therapy. Handb Exp Pharmacol 201:105-167.
24. Pietig G, Mehrens T, Hirsch JR, Cetinkaya I, Piechota H, and Schlatter E (2001) Properties and regulation of organic cation transport in freshly isolated human proximal tubules. J Biol Chem 276:33741-33746.
25. Rodvold KA, Paloucek FP, Jung D, and Gallastegui J (1987) Interaction of steady-state procainamide with H2-receptor antagonists cimetidine and ranitidine. Ther Drug Monit 9:378-383. (Pubitemid 18010764)
26. Shiga T, Hashiguchi M, Urae A, Kasanuki H, and Rikihisa T (2000) Effect of cimetidine and probenecid on pilsicainide renal clearance in humans. Clin Pharmacol Ther 67:222-228. (Pubitemid 30176379)
27. Somogyi A, McLean A, and Heinzow B (1983) Cimetidine-procainamide pharmacokinetic interaction in man: evidence of competition for tubular secretion of basic drugs. Eur J Clin Pharmacol 25:339-345. (Pubitemid 13005579)
28. Somogyi A, Stockley C, Keal J, Rolan P, and Bochner F (1987) Reduction of metformin renal tubular secretion by cimetidine in man. Br J Clin Pharmacol 23:545-551. (Pubitemid 17087957)
29. Somogyi AA, Bochner F, and Sallustio BC (1992) Stereoselective inhibition of pindolol renal clearance by cimetidine in humans. Clin Pharmacol Ther 51:379-387.
30. Somogyi AA, Hovens CM, Muirhead MR, and Bochner F (1989) Renal tubular secretion of amiloride and its inhibition by cimetidine in humans and in an animal model. Drug Metab Dispos 17:190-196. (Pubitemid 19083605)
31. Sorgel F, Granneman GR, Stephan U, and Locke C (1992) Effect of cimetidine on the pharmacokinetics of temafloxacin. Clin Pharmacokinet zvol22 (Suppl 1): 75-82.
32. Tsuda M, Terada T, Mizuno T, Katsura T, Shimakura J, and Inui K (2009a) Targeted disruption of the multidrug and toxin extrusion 1 (mate1) gene in mice reduces renal secretion of metformin. Mol Pharmacol 75:1280-1286.
33. Tsuda M, Terada T, Ueba M, Sato T, Masuda S, Katsura T, and Inui K (2009b) Involvement of human multidrug and toxin extrusion 1 in the drug interaction between cimetidine and metformin in renal epithelial cells. J Pharmacol Exp Ther 329:185-191.
34. Umehara KI, Iwatsubo T, Noguchi K, and Kamimura H (2007) Comparison of the kinetic characteristics of inhibitory effects exerted by biguanides and H2-blockers on human and rat organic cation transporter-mediated transport: Insight into the development of drug candidates. Xenobiotica 37:618-634. (Pubitemid 47037155)
35. Urakami Y, Akazawa M, Saito H, Okuda M, and Inui K (2002) cDNA cloning, functional characterization, and tissue distribution of an alternatively spliced variant of organic cation transporter hOCT2 predominantly expressed in the human kidney. J Am Soc Nephrol 13:1703-1710. (Pubitemid 34700594)
36. van Crugten J, Bochner F, Keal J, and Somogyi A (1986) Selectivity of the cimetidine-induced alterations in the renal handling of organic substrates in humans. Studies with anionic, cationic and zwitterionic drugs. J Pharmacol Exp Ther 236:481-487. (Pubitemid 16184246)
37. Wang ZJ, Yin OQ, Tomlinson B, and Chow MS (2008) OCT2 polymorphisms and in-vivo renal functional consequence: studies with metformin and cimetidine. Pharmacogenet Genomics 18:637-645.
38. Watanabe S, Tsuda M, Terada T, Katsura T, and Inui K (2010) Reduced renal clearance of a zwitterionic substrate cephalexin in MATE1-deficient mice. J Pharmacol Exp Ther 334:651-656.
39. Yamaoka K, Tanigawara Y, Nakagawa T, and Uno T (1981) A pharmacokinetic analysis program (multi) for microcomputer. J Pharmacobiodyn 4:879-885. (Pubitemid 12174128)
40. Yasui-Furukori N, Uno T, Sugawara K, and Tateishi T (2005) Different effects of three transporting inhibitors, verapamil, cimetidine, and probenecid, on fexofenadine pharmacokinetics. Clin Pharmacol Ther 77:17-23. (Pubitemid 40075385)
41. Yonezawa A and Inui K (2011) Importance of the multidrug and toxin extrusion MATE/SLC47A family to pharmacokinetics, pharmacodynamics/ toxicodynamics and pharmacogenomics. Br J Pharmacol 164:1817-1825.
42. Zhang L, Huang SM, and Lesko LJ (2011) Transporter-mediated drug-drug interactions. Clin Pharmacol Ther 89:481-484.
43. Zolk O, Solbach TF, König J, and Fromm MF (2009) Functional characterization of the human organic cation transporter 2 variant p.270Ala>Ser. Drug Metab Dispos 37:1312-1318.